“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to...
How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast,...
Can data sharing make the world a better place? Listen in to the latest episode of Few & Far Between. Biorasi CEO, Chris O'Brien,...